AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study

Benzinga02:26

• AstraZeneca stock is trending lower. Why are AZN shares declining? The updated analysis showed the camizestrant combination reduced the risk of disease progression or death by 55% compared with the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640925519?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=260,dpr=2,format=auto,quality=85/files/images/story/2026/06/02/Shanghai-china-feb-12th-2023-Astrazeneca.jpeg","is_english":true,"pubTime":"2026-06-03 02:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640925519","market":"sh","top_or_hot":-1,"title":"AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study","media":"Benzinga","content":"<div>\n<p>• AstraZeneca stock is trending lower. Why are AZN shares declining?\nThe updated analysis showed the camizestrant combination reduced the risk of disease progression or death by 55% compared with the ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/06/52952305/astrazeneca-highlights-sustained-survival-benefit-in-advanced-breast-cancer-study\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-03 02:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/06/52952305/astrazeneca-highlights-sustained-survival-benefit-in-advanced-breast-cancer-study><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>• AstraZeneca stock is trending lower. Why are AZN shares declining?\nThe updated analysis showed the camizestrant combination reduced the risk of disease progression or death by 55% compared with the ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/06/52952305/astrazeneca-highlights-sustained-survival-benefit-in-advanced-breast-cancer-study\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0757428866.USD","symbol_name":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/06/52952305/astrazeneca-highlights-sustained-survival-benefit-in-advanced-breast-cancer-study","article_id":"2640925519","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=260,dpr=2,format=auto,quality=85/files/images/story/2026/06/02/Shanghai-china-feb-12th-2023-Astrazeneca.jpeg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/06/52952305/astrazeneca-highlights-sustained-survival-benefit-in-advanced-breast-cancer-study","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640925519","pubTimestamp":1780424760,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"AstraZeneca reports updated SERENA-6 data showing camizestrant improved PFS, PFS2 and ctDNA clearance in advanced breast cancer.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4157":"电子设备和仪器","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","AEIS":"先进能源工业公司","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC"},"translate_title":"阿斯利康强调晚期乳腺癌研究的持续生存益处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEIS":1.5},"content_text":"• AstraZeneca stock is trending lower. Why are AZN shares declining?\nThe updated analysis showed the camizestrant combination reduced the risk of disease progression or death by 55% compared with the aromatase inhibitor regimen.\nMedian progression-free survival reached 16.8 months for patients receiving camizestrant, versus 9.2 months for those who remained on aromatase inhibitor therapy, representing an improvement of 7.6 months.\nFor the key secondary endpoint of second progression-free survival, the camizestrant combination reduced the risk of second disease progression or death by 37%.\nMedian second progression-free survival was 25.7 months for the camizestrant arm compared with 19.1 months in the comparator group, indicating that benefits persisted even after subsequent therapies were administered.\nThe trial also showed patients receiving camizestrant experienced a longer period before requiring more intensive treatments such as chemotherapy or antibody-drug conjugates.\nMedian chemotherapy- or ADC-free survival was 22.6 months, compared with 18.7 months for the control arm.\nExploratory analyses highlighted substantial reductions in circulating tumor DNA. \nBy week eight, patients switched to camizestrant and recorded a median 99% reduction in total ctDNA, with 51% achieving complete ctDNA clearance. \nIn contrast, patients continuing aromatase inhibitor therapy experienced a median 64% increase in total ctDNA, while only 1.9% achieved total clearance.\nOverall survival data remain immature, though results showed a numerical trend favoring the camizestrant combination. The study will continue through the final overall survival analysis.\nAZN Stock Price Activity: AstraZeneca shares were down 1.56% at $176.90 at the time of publication on Tuesday, according to Benzinga Pro.\nPhoto by Robert Way via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640925519","isCrawlerRequest":true}